These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 31014367)

  • 1. The pro- and anti-tumor roles of mesenchymal stem cells toward BRCA1-IRIS-overexpressing TNBC cells.
    Ryan D; Paul BT; Koziol J; ElShamy WM
    Breast Cancer Res; 2019 Apr; 21(1):53. PubMed ID: 31014367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Immunosuppressive Microenvironment in BRCA1-IRIS-Overexpressing TNBC Tumors Is Induced by Bidirectional Interaction with Tumor-Associated Macrophages.
    Sami E; Paul BT; Koziol JA; ElShamy WM
    Cancer Res; 2020 Mar; 80(5):1102-1117. PubMed ID: 31911557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA1-IRIS overexpression promotes and maintains the tumor initiating phenotype: implications for triple negative breast cancer early lesions.
    Sinha A; Paul BT; Sullivan LM; Sims H; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
    Oncotarget; 2017 Feb; 8(6):10114-10135. PubMed ID: 28052035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
    Blanchard Z; Paul BT; Craft B; ElShamy WM
    Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A niche that triggers aggressiveness within BRCA1-IRIS overexpressing triple negative tumors is supported by reciprocal interactions with the microenvironment.
    Ryan D; Sinha A; Bogan D; Davies J; Koziol J; ElShamy WM
    Oncotarget; 2017 Nov; 8(61):103182-103206. PubMed ID: 29262555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of BRCA1-IRIS in the development and progression of triple negative breast cancers in Egypt: possible link to disease early lesion.
    Bogan D; Meile L; El Bastawisy A; Yousef HF; Zekri AN; Bahnassy AA; ElShamy WM
    BMC Cancer; 2017 May; 17(1):329. PubMed ID: 28499366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-Stroma-Inflammation Networks Promote Pro-metastatic Chemokines and Aggressiveness Characteristics in Triple-Negative Breast Cancer.
    Liubomirski Y; Lerrer S; Meshel T; Rubinstein-Achiasaf L; Morein D; Wiemann S; Körner C; Ben-Baruch A
    Front Immunol; 2019; 10():757. PubMed ID: 31031757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Notch-Mediated Tumor-Stroma-Inflammation Networks Promote Invasive Properties and CXCL8 Expression in Triple-Negative Breast Cancer.
    Liubomirski Y; Lerrer S; Meshel T; Morein D; Rubinstein-Achiasaf L; Sprinzak D; Wiemann S; Körner C; Ehrlich M; Ben-Baruch A
    Front Immunol; 2019; 10():804. PubMed ID: 31105691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MCT-1/miR-34a/IL-6/IL-6R signaling axis promotes EMT progression, cancer stemness and M2 macrophage polarization in triple-negative breast cancer.
    Weng YS; Tseng HY; Chen YA; Shen PC; Al Haq AT; Chen LM; Tung YC; Hsu HL
    Mol Cancer; 2019 Mar; 18(1):42. PubMed ID: 30885232
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel insights linking BRCA1-IRIS role in mammary gland development to formation of aggressive PABCs: the case for longer breastfeeding.
    Castillo P; Aisagbonhi O; Saenz CC; ElShamy WM
    Am J Cancer Res; 2022; 12(1):396-426. PubMed ID: 35141026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Geminin overexpression-dependent recruitment and crosstalk with mesenchymal stem cells enhance aggressiveness in triple negative breast cancers.
    Ananthula S; Sinha A; El Gassim M; Batth S; Marshall GD; Gardner LH; Shimizu Y; ElShamy WM
    Oncotarget; 2016 Apr; 7(15):20869-89. PubMed ID: 26989079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GGNBP2 suppresses triple-negative breast cancer aggressiveness through inhibition of IL-6/STAT3 signaling activation.
    Liu J; Liu L; Yagüe E; Yang Q; Pan T; Zhao H; Hu Y; Zhang J
    Breast Cancer Res Treat; 2019 Feb; 174(1):65-78. PubMed ID: 30450530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting DCLK1 attenuates tumor stemness and evokes antitumor immunity in triple-negative breast cancer by inhibiting IL-6/STAT3 signaling.
    Liu H; Yan R; Xiao Z; Huang X; Yao J; Liu J; An G; Ge Y
    Breast Cancer Res; 2023 Apr; 25(1):43. PubMed ID: 37069669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
    Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
    Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obesity-associated metabolic inflammation promotes triple-negative breast cancer progression through the interleukin-6/STAT3/pentraxin 3/matrix metalloproteinase 7 axis.
    Xie H; Ruan G; Wei L; Zhang H; Shi J; Lin S; Liu C; Liu X; Zheng X; Chen Y; Deng L; Shi H
    Int Immunopharmacol; 2024 Jul; 136():112332. PubMed ID: 38805776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human colorectal cancer-derived mesenchymal stem cells promote colorectal cancer progression through IL-6/JAK2/STAT3 signaling.
    Zhang X; Hu F; Li G; Li G; Yang X; Liu L; Zhang R; Zhang B; Feng Y
    Cell Death Dis; 2018 Jan; 9(2):25. PubMed ID: 29348540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mesenchymal stem cell-induced doxorubicin resistance in triple negative breast cancer.
    Chen DR; Lu DY; Lin HY; Yeh WL
    Biomed Res Int; 2014; 2014():532161. PubMed ID: 25140317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways.
    Ibrahim SA; Gadalla R; El-Ghonaimy EA; Samir O; Mohamed HT; Hassan H; Greve B; El-Shinawi M; Mohamed MM; Götte M
    Mol Cancer; 2017 Mar; 16(1):57. PubMed ID: 28270211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-146a and miR-638 in BRCA1-deficient triple negative breast cancer tumors, as potential biomarkers for improved overall survival.
    Zavala V; Pérez-Moreno E; Tapia T; Camus M; Carvallo P
    Cancer Biomark; 2016; 16(1):99-107. PubMed ID: 26835710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of Carboplatin Alone and in Combination with ABT888 in Intracranial Murine Models of BRCA-Mutated and BRCA-Wild-Type Triple-Negative Breast Cancer.
    Karginova O; Siegel MB; Van Swearingen AE; Deal AM; Adamo B; Sambade MJ; Bazyar S; Nikolaishvili-Feinberg N; Bash R; O'Neal S; Sandison K; Parker JS; Santos C; Darr D; Zamboni W; Lee YZ; Miller CR; Anders CK
    Mol Cancer Ther; 2015 Apr; 14(4):920-30. PubMed ID: 25824335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.